Companies › LaNova Medicines Zhejiang
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LM-302 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma; Malignant Neoplasms of Digestive Organs | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06351020 | LM-302 | Phase 3 | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | Oncology | Nov 2026 |
| NCT05934331 | LM-302 | Phase 2 | Malignant Neoplasms of Digestive Organs | Oncology | Aug 2031 |
Biokin (Shanghai) Biopharmaceutical Hangzhou Sumgen Biotech Suzhou Immunofoco Biotechnology FutureGen Biopharmaceutical (Beijing) NingBo Junyan Hongshi Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.